Erythromycin

Contraindicated

Erythromycin Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Erythromycin Simvastatin Flolipid Explained Increased simvastatin exposure, an increased risk of simvastatin-related adverse reaction and an increased risk of myopathy or rha... Details Erythromycin Atorvastatin Atorvaliq Increased atorvastatin exposure, an increased risk of atorvastatin-related adverse reaction and an increased risk of myopathy or r... Details Erythromycin Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity (ergotism) Details Erythromycin Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity (ergotism) Details Erythromycin Ketoconazole Topical Extina® Foam Increased erythromycin exposure, an increased ketoconazole exposure and an increased risk of QT interval prolongation Details Erythromycin Lovastatin Altocor® Increased lovastatin exposure, an increased risk of lovastatin-related adverse reaction and an increased risk of myopathy or rhabd... Details

Major

Erythromycin Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Erythromycin Abametapir Explained Increased exposure of CYP3A4 substrate Details Erythromycin Clindamycin ANTIROBE Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Omeprazole Gastrobim Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Amitriptyline Elavil Explained Increased risk of QT interval prolongation Details Erythromycin Sertraline Explained An increased risk of QT interval prolongation, an increased sertraline exposure and an increased risk of sertraline-related advers... Details Erythromycin Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Erythromycin Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Erythromycin Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Erythromycin Alpelisib Piqray Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Erythromycin Apixaban Eliquis Explained Increased apixaban exposure and increased risk of bleeding Details Erythromycin Apremilast Otezla Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Arsenic Trioxide Trisenox Increased risk of QT interval prolongation Details Erythromycin Aripiprazole Injection Abilify An increased risk of QT interval prolongation, an increased ARIPiprazole or ARIPiprazole lauroxil exposure and an increased risk o... Details Erythromycin Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation Details Erythromycin Asciminib Scemblix Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Erythromycin Atogepant Qulipta Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Erythromycin Avatrombopag Doptelet Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Azithromycin AzaSite An increased risk of QT interval prolongation Details Erythromycin Belumosudil Rezurock Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Betrixaban Bevyxxa® Increased betrixaban exposure and increased risk of bleeding Details Erythromycin Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Erythromycin Abiraterone Abirtega Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Afatinib Gilotrif Increased exposure of afatinib Details Erythromycin Aficamten Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Erythromycin Alfuzosin UroXatral An increased risk of QT interval prolongation, an increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-re... Details Erythromycin Amlodipine Amvaz® Increased amLODIPine exposure, an increased amLODIPine-related adverse reactions and an increased risk of hypotension Details Erythromycin Anagrelide Agrylin Increased risk of QT interval prolongation Details Erythromycin Ascorbic Acid (Vitamin C) C-500® Chewable Tablet Decreased erythromycin efficacy Details Erythromycin Avanafil Stendra Increased avanafil exposure and an increased risk of avanafil-related adverse effects Details